Can continuous glucose monitoring be used as a new tool for diagnosing white coat hyperglycaemia and possibly some other entities?

Introduction. Since 1999 continuous glucose monitoring (CGM) has been used to measure the amount of in interstitial fluid. CGM is crucial when it comes developing ambulatory profile and giving information on time spent range (TIR), percentage above below range, as well variability. Discussion. It was 1992 that Campbell et al. first described white coat hyperglycaemia, who explained patients having elevated blood levels a clinician's office or laboratory normal obtained by self-monitoring. Prior introduction CGM, hyperglycaemia discrepancy self-monitoring (SMBG). Nowadays, may be said patient they have SMBG TIR 70% CGM. Recognising importance for treatment its intensification based glycaemia alone can lead episodes hypoglycaemia potentially lethal outcome. Should comparison made with arterial hypertension pressure (ABPM), provide several other options: 1) masked hyperglycaemia; 2) isolated nocturnal hyperglycaemia. Conclusion. seems logical diagnosing possibly some (new) entities. Nonetheless, clinical significance all these entities only discussed after conducting adequately designed randomised trials, which we would strongly encourage.